34,533 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners LLC cut its Alnylam Pharmaceuticals stake by 96.9% in the third quarter, selling 34,533 shares and retaining 1,095 shares valued at approximately $270,000.
• Institutional ownership remains high at 92.97%, with several major investors initiating positions and Wellington Management increasing its stake by 9%.
• Alnylam reported quarterly EPS of $1.84, exceeding estimates, while revenue rose 66.9% year over year to $1.29 billion. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $364.95.

Curated Wealth Partners LLC decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 96.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,095 shares of the biopharmaceutical company's stock after selling 34,533 shares during the period. Curated Wealth Partners LLC's holdings in Alnylam Pharmaceuticals were worth $270,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALNY. Legal & General Group Plc acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $278,321,000. Bank of New York Mellon Corp bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $148,128,000. Canada Pension Plan Investment Board acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $100,618,000. Korea Investment CORP acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $74,553,000. Finally, Wellington Management Group LLP boosted its position in shares of Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock worth $635,296,000 after buying an additional 174,482 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the company's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $231.83 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock's 50-day simple moving average is $239.35 and its 200 day simple moving average is $274.34. The company has a market cap of $31.02 billion, a P/E ratio of 43.09 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the prior year, the company posted ($0.51) earnings per share. Alnylam Pharmaceuticals's revenue was up 66.9% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of research reports. Needham & Company LLC decreased their price objective on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Truist Financial cut their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating on the stock in a research note on Tuesday, August 4th. Stifel Nicolaus cut their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a "buy" rating on the stock in a research note on Friday, July 31st. UBS Group began coverage on Alnylam Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $354.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an "overweight" rating for the company in a research note on Wednesday, September 30th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $364.95.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.